Skip Navigation

Neuro-Oncology 2009 11(1):92-95; doi:10.1215/15228517-2008-071
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Norden, A. D.
Right arrow Articles by Wen, P. Y.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Norden, A. D.
Right arrow Articles by Wen, P. Y.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright 2009 by the Society for Neuro-Oncology

Colon perforation during antiangiogenic therapy for malignant glioma

Andrew D. Norden, Jan Drappatz, Abigail Slate Ciampa, Lisa Doherty, Debra Conrad LaFrankie, Santosh Kesari and Patrick Y. Wen

Division of Neuro-Oncology, Department of Neurology, Brigham and Women's Hospital, Boston, MA (A.D.N., J.D., S.K., P.Y.W.); Center for Neuro-Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA (A.D.N., J.D., A.S.C., L.D., D.C.L., S.K., P.Y.W.); Harvard Medical School, Boston, MA, (A.D.N., J.D., S.K., P.Y.W.); USA

Address correspondence to Andrew D. Norden, Center for Neuro-Oncology, Dana-Farber Cancer Institute, 44 Binney St., Boston, MA 02115, USA (anorden{at}partners.org).


  Abstract

Antiangiogenic drugs have emerged as effective treatment options for patients with recurrent malignant gliomas (MGs). Though this class of drugs is generally well tolerated, rare life-threatening complications, including thromboembolism, hemorrhage, and gastrointestinal (GI) perforation, are reported. We describe six cases of GI perforation among 244 glioma patients (2.5%) during treatment with antiangiogenic agents in combination with chemotherapy and corticosteroids. Two patients succumbed to this complication, and the others recovered. Because GI perforation is a life-threatening yet treatable complication, neurooncologists must have a low threshold to consider it in patients on antiangiogenic drug therapy who present with abdominal pain and other GI complaints.

Keywords: antiangiogenic drugs, bevacizumab, gastrointestinal perforation, malignant glioma

Received March 25, 2008; Accepted July 8, 2008


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.